Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roivant Sciences (NASDAQ:ROIV – Free Report) had its price objective increased by Deutsche Bank Aktiengesellschaft from $14.00 to $15.00 in a report released on Wednesday, Benzinga reports. They currently have a buy rating on the stock. ROIV has been the subject of several other reports. Piper Sandler started coverage on Roivant Sciences in a research […]
Roivant Sciences (NASDAQ:ROIV – Free Report) had its price target upped by HC Wainwright from $17.00 to $18.00 in a research note released on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Roivant Sciences’ Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings […]
Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit related to Moderna's blockbuster COVID-19 vaccines. ...
(Reuters) -Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus' arguments in a patent infringement lawsuit ...